PACE-CME

4-year follow-up data on efficacy and safety of PCSK9 siRNA

year followup data on efficacy and safety of PCSK siRNA
RestartResume
5' education - May 8, 2023 - Kausik Ray, MD
  • Overview

    After the ORION-1 trial, participants were invited to participate in the ORION-3 trial. This was an open-label extension study of 4 years in which the long-term effects of inclisiran were investigated.

  • Educational information

    This video was recorded in response to the publication in Lancet Diabetes Endocrinol. by Kausik Ray and colleagues.

  • Faculty

    Prof. Kausik Ray, MD is Professor of Public Health and Consultant Cardiologist at Imperial College London, UK.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Find the publication of ORION -3 online at Lancet Diabetes Endocrinol

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free